scholarly journals Lymphoepithelial carcinoma of the larynx: An unusual response to EXTREME regimen therapy. A new option for treatment?

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Daniele Bugada ◽  
Lucrezia Trozzi ◽  
Davide Renna ◽  
Gerardo Petruzzi ◽  
Barbara Pichi ◽  
...  
Keyword(s):  
Treatment Guidelines ◽  
Clinical Course ◽  
Undifferentiated Carcinoma ◽  
Glottic Cancer ◽  
Lymphoepithelial Carcinoma ◽  
High Propensity ◽  
Lymphoplasmacytic Infiltrate ◽  
Carcinoma Of The Larynx ◽  
Disease Free ◽  
Aggressive Variant

Lymphoepithelial Carcinoma (LEC), an aggressive variant of Squamous Cell Carcinoma (SCC), is an undifferentiated carcinoma with an intermixed reactive lymphoplasmacytic infiltrate. Most cases of LEC occur in the nasopharynx, while it rarely involves other sites. LEC of larynx and hypopharynx is an extremely rare and aggressive neoplasm, characterized by a high propensity to loco-regional dissemination and a poor prognosis; it represents the 0,2% of all tumours of the larynx. Since it is such a rare tumor, the current literature provides only recommendations and there are no treatment guidelines available. A 70-year-old man with laryngeal LEC and both distant and nodal metastases was treated with chemotherapy, following EXTREME regimen therapy. It was classified as a cT3 N3b M1 glottic cancer (Stage IVC, AJCC 8th Ed.), stage IVC. As the response on metastases was unexpectedly encouraging, surgical treatment on T could be performed. Patient underwent to total laryngectomy and bilateral neck dissection. To date, eight months after surgery, the patient is disease free. The unusual clinical course is reported.

scholarly journals Lymphoepithelial Carcinoma of the Palatine Tonsil

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Milica Jevtić ◽  
Dejan Milić ◽  
Marina Jovanović ◽  
Nenad Relić ◽  
Andra Jevtović ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Rare Case ◽  
Cervical Lymphadenopathy ◽  
Undifferentiated Carcinoma ◽  
Concurrent Chemotherapy ◽  
Palatine Tonsil ◽  
Histopathological Analysis ◽  
Lymphoepithelial Carcinoma ◽  
Lymphoplasmacytic Infiltrate ◽  
The Right

Abstract Lymphoepithelial carcinoma is an undifferentiated carcinoma with nonneoplastic lymphoplasmacytic infiltrate, mostly located in the nasopharynx, while it is extremely rare in the oropharynx. We present a rare case of lymphoepithelial carcinoma arising from palatine tonsil. A 81-year old male patient complained of dysphagia, hypersalivation and bloody sputum. Clinical examination revealed hypertrophy of the right palatine tonsil and ipsilateral cervical lymphadenopathy. Biopsy and histopathological analysis confirmed the diagnosis of lymphoepithelial carcinoma. Multi-slice computed tomography showed a 33x31x38 mm heterodense mass in the region of the right palatine tonsil, and 37x30 mm and 21x20 mm lymph nodes on the right side of the neck. The patient was reffered to an oncology council, which suggested radiotherapy and concurrent chemotherapy. Although rare in clinical practice, lymphoepithelial carcinoma should be considered in cases of tonsil cancer.

scholarly journals Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer

Cells ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 1073 ◽  
Author(s):  
Rodolfo Montironi ◽  
Alessia Cimadamore ◽  
Antonio Lopez-Beltran ◽  
Marina Scarpelli ◽  
Gaetano Aurilio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Final Diagnosis ◽  
Undifferentiated Carcinoma ◽  
Castration Resistant Prostate Cancer ◽  
Platinum Based Chemotherapy ◽  
Intermediate Part ◽  
Aggressive Variant

The term aggressive variant prostate cancer (AVPCa) refers to androgen receptor (AR)-independent anaplastic forms of prostate cancer (PCa), clinically characterized by a rapidly progressive disease course. This involves hormone refractoriness and metastasis in visceral sites. Morphologically, AVPCa is made up of solid sheets of cells devoid of pleomorphism, with round and enlarged nuclei with prominent nucleoli and slightly basophilic cytoplasm. The cells do not show the typical architectural features of prostatic adenocarcinoma and mimic the undifferentiated carcinoma of other organs and locations. The final diagnosis is based on the immunohistochemical expression of markers usually seen in the prostate, such as prostate-specific membrane antigen (PSMA). A subset of AVPCa can also express neuroendocrine (NE) markers such as chromogranin A, synaptophysin and CD56. This letter subset represents an intermediate part of the spectrum of NE tumors which ranges from small cell to large cell carcinoma. All such tumors can develop following potent androgen receptor pathway inhibition. This means that castration-resistant prostate cancer (CRPCa) transdifferentiates and becomes a treatment-related NE PCa in a clonally divergent manner. The tumors that do not show NE differentiation might harbor somatic and/or germline alterations in the DNA repair pathway. The identification of these subtypes has direct clinical relevance with regard to the potential benefit of platinum-based chemotherapy, poly (ADP-ribose) polymerase inhibitors and likely further therapies.

Undifferentiated Carcinoma with Lymphoid Stroma of the Major Salivary Glands

1990 ◽  
Vol 99 (3) ◽  
pp. 236-238 ◽  
Author(s):  
Karen R. Cleary ◽  
John G. Batsakis
Keyword(s):  
Salivary Glands ◽  
Epstein Barr Virus ◽  
Undifferentiated Carcinoma ◽  
Response To Therapy ◽  
Lymphoepithelial Carcinoma ◽  
Lymphoepithelial Lesion ◽  
Barr Virus ◽  
Lymphoid Stroma ◽  
Major Salivary Glands ◽  
Epstein Barr

Undifferentiated carcinoma with lymphoid stroma or lymphoepithelial carcinoma of the major salivary glands is a demographically and histopathologically unique malignancy. Although whites may have the disease, it is preponderantly a carcinoma of North American Eskimos and native Greenlanders. The carcinoma shares many features with undifferentiated nasopharyngeal carcinomas, from which it must be distinguished: histologic appearance, putative relationship with Epstein-Barr virus, predilection for mongoloid races, and response to therapy. In some cases, the carcinoma appears to have evolved from a lymphoepithelial lesion.

scholarly journals Primary renal embryonal rhabdomyosarcoma in an adult patient

2020 ◽  
Vol 13 (1) ◽  
pp. e231000
Author(s):  
Jessica Connor ◽  
Johnson F Tsui ◽  
Wenlei He ◽  
Ravi Munver
Keyword(s):  
Adult Patient ◽  
Radical Nephrectomy ◽  
Treatment Guidelines ◽  
Clinical Course ◽  
Embryonal Rhabdomyosarcoma

Adult renal rhabdomyosarcoma (RMS) is a rare and aggressive entity with a paucity of data and reports in the literature. As a result, treatment guidelines for this malignancy are not well-established. Herein, we present the diagnosis, management and clinical course of a 39-year-old patient diagnosed with primary renal embryonal RMS (ERMS) following radical nephrectomy. We also review the existing literature on primary renal ERMS.

scholarly journals Epstein-Barr virus-associated lymphoepithelial carcinoma of the larynx

2015 ◽  
Vol 132 (4) ◽  
pp. 231-233 ◽  
Author(s):  
Wassim Kermani ◽  
Malek Belcadhi ◽  
Badreddine Sriha ◽  
Mouhamed Abdelkéfi
Keyword(s):  
Epstein Barr Virus ◽  
Lymphoepithelial Carcinoma ◽  
Barr Virus ◽  
Carcinoma Of The Larynx ◽  
Epstein Barr

scholarly journals Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours

2020 ◽  
Vol 36 (5) ◽  
pp. 359-363
Author(s):  
Jens Ricke ◽  
Christoph Benedikt Westphalen ◽  
Max Seidensticker
Keyword(s):  
Treatment Guidelines ◽  
Local Treatment ◽  
Disease Free Survival ◽  
Free Survival ◽  
Organ Systems ◽  
Therapeutic Concepts ◽  
Gastrointestinal Tumours ◽  
Definition Of ◽  
Disease Free ◽  
Systemic Therapies

<b><i>Background:</i></b> Clinical trials have proven a survival benefit from applying local therapies for oligometastatic cancers of various origin. <b><i>Summary:</i></b> Today, the definition of oligometa­static disease is based on limited lesion numbers and organ systems involved. Treatment guidelines by the European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO) and several other groups suggest a threshold of up to 5 tumours. Established biological markers indicating the aggressiveness of a given tumour (and therefore suggesting local treatment only or the addition of or complete switch to systemic therapies) are missing, except for disease-free survival, the only recommended parameter for patient selection beyond lesion count. <b><i>Key Message:</i></b> The following article discusses clinical implications as well as local techniques established for the treatment of oligometastatic disease.

Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma.

1986 ◽  
Vol 4 (5) ◽  
pp. 710-715 ◽  
Author(s):  
E C Holmes ◽  
M Gail
Keyword(s):  
Weight Loss ◽  
Disease Free Survival ◽  
Large Cell ◽  
Undifferentiated Carcinoma ◽  
Stage Ii ◽  
Free Survival ◽  
Lung Cancer Study Group ◽  
Resected Stage ◽  
To Receive ◽  
Disease Free

The Lung Cancer Study Group randomized 141 patients with resected stage II and III adenocarcinoma and large-cell undifferentiated carcinoma to receive postoperative Cytoxan (Bristol-Meyers, Syracuse, NY), Adriamycin (Adria Laboratories, Columbus, Ohio), and cisplatin (CAP) chemotherapy or bacillus Calmette-Guerin (BCG) and levamisole immunotherapy. Careful intraoperative staging was performed on all patients. Before randomization, patients were stratified by stage, weight loss, cardiac arrhythmia, and institution. Prognostic variables such as stage, age, weight loss, and nodal involvement were equally distributed between the two groups. Disease-free survival was significantly prolonged in the group receiving chemotherapy. There was no evidence of a deleterious effect of the immunotherapy. This study indicates that postoperative CAP chemotherapy is effective in prolonging disease-free survival in these patients.

scholarly journals High-Grade Sinonasal Carcinoma: Classification Through Molecular Profiling

2019 ◽  
Vol 143 (11) ◽  
pp. 1416-1419 ◽  
Author(s):  
Julie Guilmette ◽  
Peter M. Sadow
Keyword(s):  
Molecular Profiling ◽  
Undifferentiated Carcinoma ◽  
Clinical Impact ◽  
High Grade ◽  
Lymphoepithelial Carcinoma ◽  
Nut Midline Carcinoma ◽  
Sinonasal Carcinoma ◽  
Epithelial Neoplasms ◽  
Well Differentiated ◽  
Tumor Entities

High-grade sinonasal carcinomas are a cohort of malignant epithelial neoplasms arising in the sinonasal cavities with distinct, ominous morphologic features or lacking well-differentiated features that might otherwise classify them as less biologically worrisome. Recent advances in molecular profiling have led to the identification of several distinct tumor entities previously grouped together. These molecularly distinct lesions include NUT (midline) carcinoma, INI1 (SMARCB1)-deficient carcinoma, SMARCA4-deficient sinonasal carcinoma, and novel IDH-mutant sinonasal undifferentiated carcinoma, in addition to the previously described lymphoepithelial carcinoma that may also be included in the differential diagnosis. The discovery of these distinct molecular tumor profiles may have significant clinical impact as targeted molecular-based therapeutics continue to evolve, and they may offer some respite for patients who have these highly aggressive cancers.

Twelve cases of glottic carcinoma in situ treated by radiotheraphy: an observation on clinical course versus response

1993 ◽  
Vol 107 (11) ◽  
pp. 1014-1016 ◽  
Author(s):  
J. P. Brooks ◽  
D. W. Morgan ◽  
J. Glaholm
Keyword(s):  
Carcinoma In Situ ◽  
Clinical Course ◽  
Alternative Methods ◽  
Glottic Carcinoma ◽  
Methods Of Treatment ◽  
Disease Free ◽  
Long Term Studies

AbstractCarcinoma in Situ (CIS) of the glottis is an uncommon and poorly understood condition with few, large, long- term studies. Twelve cases are presented which were treated with radiotherapy. At three-year follow-up all the patients are disease free and in 83 per cent the mucosa has returned to normal. The alternative methods of treatment are discussed.

Sign in / Sign up

Export Citation Format

Share Document